MITHRA PHARMACEUTICALS S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2215 EUR | -2.42% |
|
+0.45% | -82.34% |
| Apr. 22 | Mithra Pharmaceuticals Obtains Court Protection Measures | MT |
| Mar. 08 | Mithra Pharmaceuticals SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Mithra Pharmaceuticals S.A. explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, the Company is now focusing on its second product Donesta®, the next-generation hormone therapy.
Mithra Pharmaceuticals S.A. also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO.
Number of employees: 270
Sales per Business
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Therapeutic Products
100.0
%
| 23 | 100.0 % | 67 | 100.0 % | +195.56% |
Sales per region
| EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
|---|---|---|---|---|---|
Europe
76.6
%
| 9 | 41.0 % | 51 | 76.6 % | +452.76% |
International
21.1
%
| 12 | 54.6 % | 14 | 21.1 % | +14.23% |
Belgium
2.3
%
| 1 | 4.5 % | 2 | 2.3 % | +51.98% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 17-02-22 | |
Stijn Vlaminck
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-30 |
Graham Dixon
CTO | Chief Tech/Sci/R&D Officer | 63 | 19-03-31 |
Fanny Rozenberg
SEC | Corporate Secretary | - | - |
Laurence Schyns
HRO | Human Resources Officer | - | 20-12-31 |
Cedric Darcis
LAW | General Counsel | - | - |
Benjamin Brands
PRN | Corporate Officer/Principal | - | 08-12-31 |
| Corporate Officer/Principal | - | 12-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jacques Galloy
BRD | Director/Board Member | 53 | 23-05-28 |
Christian Homsy
CHM | Chairman | 65 | 23-05-28 |
Valérie Gordenne
BRD | Director/Board Member | 51 | 21-05-19 |
| Founder | 75 | 99-07-07 | |
Inge Beernaert
BRD | Director/Board Member | - | 23-05-28 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 69,108,397 | 56,443,924 ( 81.67 %) | 0 | 81.67 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
| 4,221,815 | 4.96% | 19,941,237 $ |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Estetra SRL
 Estetra SRL Pharmaceuticals: MajorHealth Technology Part of Mithra Pharmaceuticals SA, Estetra SRL is a Belgian pharmaceutical company that develops drugs. The private company is based in Grâce-Hollogne, Belgium. |
Pharmaceuticals: Major
|
Sector
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
0.2215
EUR
Average target price
0.11
EUR
Spread / Average Target
-50.34%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -82.34% | 16.79M | |
| -2.86% | 87.37B | |
| +3.95% | 41.01B | |
| -21.94% | 28.08B | |
| +53.11% | 24.72B | |
| -5.41% | 17.47B | |
| -44.23% | 11.69B | |
| -17.60% | 11.6B | |
| -13.96% | 11.56B | |
| -0.22% | 8.44B |
- Stock Market
- Equities
- MITRA Stock
- Company Mithra Pharmaceuticals S.A.
